|Bid||56.86 x 800|
|Ask||60.60 x 900|
|Day's range||55.52 - 57.28|
|52-week range||41.85 - 73.99|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||11.78|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Buying quality merchandise when it's on sale is a stock market strategy used by some of the greatest investors in the world - including Warren Buffett. After t...
Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.
Shares in Henry Schein Inc (NSQ:HSIC) are currently trading at 54.03 but a key question for investors is how the economic uncertainty caused by Coronavirus wil8230;
With me on the call today are Stanley Bergman, chairman of the board and chief executive officer of Henry Schein; and Steven Paladino, executive vice president and chief financial officer. Before we begin, I would like to state that certain comments made during this call will include information that is forward looking.
Unfortunately for some shareholders, the Henry Schein (NASDAQ:HSIC) share price has dived 30% in the last thirty days...
Henry Schein, Inc. (NASDAQ:HSIC) shares fell 6.4% to US$67.54 in the week since its latest annual results. It looks...
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How far off is Henry Schein, Inc. (NASDAQ:HSIC) from its intrinsic value? Using the most recent financial data, we'll...
Today we'll evaluate Henry Schein, Inc. (NASDAQ:HSIC) to determine whether it could have potential as an investment...
Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.
We'd be surprised if Henry Schein, Inc. (NASDAQ:HSIC) shareholders haven't noticed that an insider, Paul Brons...
Henry Schein (HSIC) delivered earnings and revenue surprises of 4.65% and -0.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.